Harnessing OcuLief Technology to Improve Retinal Drug Durability, Reduce Treatment Burden & Enhance Patient Outcomes

• Explore how Re-Vana’s OcuLief technology enables a high-payload liquid formulation to be delivered through a conventional intravitreal injection and rapidly transformed into a solid implant using visible light, providing sustained drug release directly within the eye
• Understand how OcuLief is designed to overcome the limitations of frequent intravitreal injections by extending therapeutic durability, maintaining local drug exposure, and supporting improved patient adherence in retinal disease management
• Assess the clinical, manufacturing, and regulatory considerations associated with translating light-activated sustained-release implants into practice and discover what is required to achieve broad clinical adoption and commercial success in ophthalmology

Speakers: